Abstract
Background & Objective: Gliomas constitute 81% of malignant brain tumors and exhibit a poor prognosis. Two main events involved in the progression of gliomas are the deregulation of genes via genetic events and the cellular damage resulting from the formation of reactive oxygen species (ROS). In gliomas, epigenetic abnormalities implicated in the deregulation of deoxyribonucleic acid (DNA) methylation, nucleosome rearrangement, and acetylation of histones, have been depicted. The overproduction of ROS has been implicated in the promotion of these modifications.
Conclusion: In this review, we discuss the epigenetic mechanisms and oxidative events that impact gene silencing and its association with the establishment and development of gliomas. Some of these epigenetic marks, or their related proteins, are under investigation for their potential use as biomarkers in clinical trials to propose personalized therapies for patients with glioblastoma.
Keywords: Brain tumors, clinical trials, epigenetics, glioma, malignant, oxidative stress.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Role of Epigenetics and Oxidative Stress in Gliomagenesis
Volume: 16 Issue: 10
Author(s): Yesennia Sanchez-Perez, Ernesto Soto-Reyes, Claudia M. Garcia-Cuellar, Bernardo Cacho-Diaz, Abel Santamaria and Edgar Rangel-Lopez*
Affiliation:
- National Institute of Neurology and Neurosurgery, Laboratory of Excitatory Amino Acids. Av. Insurgentes Sur #3877 Col. La Fama. Delegacion Tlalpan, C.P. 14269 Mexico City,United States
Keywords: Brain tumors, clinical trials, epigenetics, glioma, malignant, oxidative stress.
Abstract: Background & Objective: Gliomas constitute 81% of malignant brain tumors and exhibit a poor prognosis. Two main events involved in the progression of gliomas are the deregulation of genes via genetic events and the cellular damage resulting from the formation of reactive oxygen species (ROS). In gliomas, epigenetic abnormalities implicated in the deregulation of deoxyribonucleic acid (DNA) methylation, nucleosome rearrangement, and acetylation of histones, have been depicted. The overproduction of ROS has been implicated in the promotion of these modifications.
Conclusion: In this review, we discuss the epigenetic mechanisms and oxidative events that impact gene silencing and its association with the establishment and development of gliomas. Some of these epigenetic marks, or their related proteins, are under investigation for their potential use as biomarkers in clinical trials to propose personalized therapies for patients with glioblastoma.
Export Options
About this article
Cite this article as:
Sanchez-Perez Yesennia, Soto-Reyes Ernesto , Garcia-Cuellar M. Claudia, Cacho-Diaz Bernardo , Santamaria Abel and Rangel-Lopez Edgar *, Role of Epigenetics and Oxidative Stress in Gliomagenesis, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527317666180110124645
DOI https://dx.doi.org/10.2174/1871527317666180110124645 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Elaborating the Role of Natural Products on the Regulation of Autophagy and their Potentials in Breast Cancer Therapy
Current Cancer Drug Targets Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
Current Cancer Drug Targets Tumor Initiating Cells
Current Pharmaceutical Biotechnology Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Progress in Research of K<sub>V</sub>1.1 and K<sub>V</sub>1.3 Channels as Therapeutic Targets
Current Topics in Medicinal Chemistry Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Editorial [Hot Topic: SOD Enzymes and Their Mimics in Cancer: Pro- vs Anti-Oxidative Mode of Action-Part I (Guest Editor: Ines Batinic-Haberle)]
Anti-Cancer Agents in Medicinal Chemistry Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products
Current Medicinal Chemistry Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy
Current Drug Metabolism Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Recent Developments of Phototherapy Based on Graphene Family Nanomaterials
Current Medicinal Chemistry Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology G-Quadruplex Interacting Agents Targeting the Telomeric G-Overhang Are More than Simple Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Reconceptualizing Adult Neurogenesis: Role for Sphingosine-1-Phosphate and Fibroblast Growth Factor-1 in Co-Ordinating Astrocyte-Neuronal Precursor Interactions
CNS & Neurological Disorders - Drug Targets